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Neuro-Oncology
Brain metastasis, which occurs in 20% to 40% of all can-
cer patients, is an important cause of neoplastic morbidity
and mortality. Successful invasion into the brain by tumor
cells must include attachment to microvessel endothelial
cells, penetration through the blood-brain barrier, and, of
relevance, a response to brain survival and growth factors.
Neurotrophins (NTs) are important in brain-invasive
steps. Human melanoma cell lines express low-affinity 
NT receptor p75NTR in relation to their brain-metastatic
propensity with their invasive properties being regulated
by NGF, or nerve growth factor, the prototypic NT. They
also express functional TrkC, the putative receptor for the
invasion-promoting NT-3. In brain-metastatic melanoma
cells, NTs promote invasion by enhancing the production
of extracellular matrix (ECM)-degradative enzymes such
as heparanase, an enzyme capable of locally destroying
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both ECM and the basement membrane of the blood-
brain barrier. Heparanase is an endo--d-glucuronidase
that cleaves heparan sulfate (HS) chains of ECM HS pro-
teoglycans, and it is a unique metastatic determinant
because it is the dominant mammalian HS degradative
enzyme. Brain-metastatic melanoma cells also produce
autocrine/paracrine factors that influence their growth,
invasion, and survival in the brain. Synthesis of these fac-
tors may serve to regulate NT production by brain cells
adjacent to the neoplastic invasion front, such as astro-
cytes. Increased NT levels have been observed in tumor-
adjacent tissues at the invasion front of human brain
melanoma. Additionally, astrocytes may contribute to the
brain-metastatic specificity of melanoma cells by produc-
ing NT-regulated heparanase. Trophic, autocrine, and
paracrine growth factors may therefore determine whether
metastatic cells can successfully invade, colonize, and grow
in the CNS. Neuro-Oncology 6, 154–165, 2004 (Posted
to Neuro-Oncology [serial online], Doc. 03-067, March
4, 2004. URL http://neuro-oncology.mc.duke.edu; DOI:
10.1215/S1152 8517 03 00067 X)
Brain metastases represent a major cause of death incancer patients and a significant area of cancerbiology research: They occur in 20% to 40% of
cancer cases, and their frequency is yearly increasing.
Though no single clinical therapy is preferentially supe-
rior, surgical excision, radiation, and/or chemotherapy
are most commonly applied in patients with a resected
primary tumor and single/multiple brain metastases. Ir-
respective of treatment, the prognosis for patients with
brain metastasis is grim (Prados and Wilson, 1993;
Sawaya et al., 1996; Soffietti et al., 2002). CNS involve-
ment is a common feature of metastatic melanoma. The
high CNS involvement associated with malignant mela-
noma may be due to a “homing” influence since mela-
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Malignant melanomas, particularly those that advance
to the brain, undergo progressive changes during their
pathogenesis. Of the phenotypic changes that occur dur-
ing metastatic melanoma progression, differences in the
expression of receptors for paracrine growth factors and
in the production of various autocrine growth factors are
important (Albino et al., 1991; Herlyn et al., 1985). Al-
though the significance of these factors in modulating the
malignant properties exhibited by melanoma cells remains
largely unknown, they are thought to be relevant in
allowing malignant cells to survive in unusual compart-
ments such as the brain. Neurotrophins (NTs) are growth
factors that promote neuronal cell survival, differentia-
tion, and cell death (Bradshaw et al., 1993; Lee et al.,
2001; Raff, 1992; Raff et al., 1993; Snider, 1994).  The
involvement of NTs, neurotrophin receptors (NTRs), and
NT-regulated heparanase in the development of brain
metastasis is the subject of this review.
Neurotrophins and Neurotrophin Receptors
Nerve growth factor (NGF), the prototypic NT, is 1 of
the 4 members that make up the mammalian NT fam-
ily. The other NTs, brain-derived neurotrophic growth
factor (BDNF), NT-3, and NT-4/5 (NT-5 is the mamma-
lian homolog of Xenopus NT-4), share at least 50%
amino acid homology with NGF, and they are all highly
conserved in the region of the central axis of the mole-
cule (Bradshaw et al., 1993). Neurotrophins are a family
of small (13 kDa), highly basic (pI 9–10.5) proteins
that are synthesized as pre-propeptides and subsequently
N-terminally processed to contain 3 interchain disulfide
bonds (Bradshaw et al., 1993). Each protein monomer
contains an elongated central axis made of an antipar-
allel -sheet structure with a flattened hydrophobic face
that is involved in dimer formation (Bradshaw et al.,
1993). It is this 26-kDa homodimer that is the circulat-
ing form of NTs. The recent discovery that NT precursor
proteins and their proteolytically processed products may
differentially activate pro-apoptotic and anti-apoptotic
cellular responses, via preferential activation of NT
receptors, promises to unveil yet another level of regu-
latory complexity (Lee et al., 2001). 
Neurotrophin receptors have been historically divided
into 2 affinity classes (Chao and Bothwell, 2002), a low-
affinity receptor class (nerve growth factor receptor
[NGFR] or p75NTR, KD  2  10
-9) and a high-affinity
receptor class (TrkA, TrkB, and TrkC, KD  2  10
-11;
Fig. 2; Table 1). Because of the formation of homodimers
and heterodimers between the high-affinity and low-
affinity receptor classes, the historical designation is an
oversimplification of an increasingly complex system. 
The low-affinity receptor p75NTR is capable of bind-
ing all members of the NT family (Fig. 3; Table 1), and it
mediates cellular responses to NT dimers in neuronal tis-
sues (Chao and Bothwell, 2002). Cloned by Chao and
coworkers (Johnson et al., 1986), the human gene en-
codes a 75-kDa cell-surface glycoprotein that, as sequence
analysis revealed, lacks a tyrosine kinase (TK) consensus
sequence (Johnson et al., 1986). However, despite the
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nocytes and neuronal subpopulations share a common
embryologic origin (Fig. 1; Herlyn et al., 1985). Malig-
nant melanoma metastasizes to the brain with one of the
highest frequencies of any cancer capable of colonizing
the CNS. Patients with disseminated malignant mela-
noma frequently develop metastatic lesions in the brain
and spinal cord that can result in severe and debilitating
neurological complications (Sawaya et al., 1996; Soffietti
et al., 2002). Once melanoma cells colonize the brain,
tumor growth often results in a rapid decline in the qual-
ity of life, and death ensues: Almost 40% of melanoma
patients will be treated for complications due to brain
metastases. At autopsy, an additional 30% to 40% of
patients show CNS lesions (Sawaya et al., 1996; Soffi-
etti et al., 2002).
The brain, because of its anatomical and physiologi-
cal properties, provides a unique target for metastasis
(Steck and Nicolson, 1993). Homeostasis in the brain 
is highly sensitive to the slightest change in the local
microenvironment because of confinement by the skull
and the lack of an extensive lymphatic drainage system.
Furthermore, the brain is surrounded by a formidable
blood-brain barrier (BBB)3 through which brain-metasta-
tic tumor cells must penetrate. The BBB is composed of
tight junctions between brain endothelial cells, a rela-
tively thick basement membrane (BM), and an underly-
ing layer of astrocytes that strictly regulate the flow of
ions, nutrients, and cells into the brain. Thus, to suc-
cessfully colonize the brain, metastatic cells must com-
plete a series of sequential and selective steps resulting 
in subpopulations of cells with different angiogenic, inva-
sive, and metastatic properties (Fidler and Kripke, 1977).
To produce brain metastases, tumor cells must reach the
vasculature of the brain, attach to microvessel endothe-
lial cells, extravasate into the parenchyma, induce angio-
genesis, and proliferate by responding to growth factors
(Nicolson et al., 1996; Yano et al., 2000). In addition to
the above criteria, brain metastases must be able to cross
the BBB and flourish in spite of inadequate lymphatic
drainage.
Fig. 1. Embryologic relationship between melanocytes and the most
common neuronal cell populations, both being neural-crest derived.
Neuronal populations are neurotrophin-responsive and possess specific
cell-surface neurotrophin receptors. Examples include neurons of
peripheral nervous system sensory and sympathetic ganglia, Schwann
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absence of a TK domain, transfection of p75NTR into
non-neuronal cells was shown to enhance TK phosphor-
ylation following NGF stimulation (Ohmichi et al.,
1992a). The p75NTR provides differentiation and survival
cues to neuronal tissues (Chao and Bothwell, 2002). Fur-
thermore, the molecule possesses a signaling function
involving ceramide (Chao, 1992) that operates inde-
pendently of the high-affinity tropomyosin receptor kinase
(TRK) receptors (Barrett and Bartlett, 1994; Chao, 1992;
Saltiel et al., 1994; Verdi et al., 1994). In addition,
p75NTR provides retrograde transport to neuronal cell
types, which triggers apoptosis in certain virally trans-
formed neuronal cells (Rabizadeh et al., 1993) or survival
when expressed in neutrophils (Kannan et al., 1992). 
Original studies established that the biological effects
of NGF involve TK activity (Maher, 1988; Miyasaka et
al., 1990). The search for a high-affinity NGF receptor
with TK activity led to the discovery of the TRK family
of NTRs (Barbacid, 1993; Chao, 1992; Meakin and
Shooter, 1992; Saltiel and Decker, 1994). This family of
tyrosine receptor protein kinases consists of several re-
ceptor molecules with varying degrees of specificity for
the different members of the NT family. The TRK family
members are widely distributed in neuronal tissues and
hematopoietic cells (Barbacid, 1993; Chao, 1992;
Meakin and Shooter, 1992; Saltiel and Decker, 1994).
Each receptor selectively binds only a subset of the NTs
(Table 1), all functions of which have been derived from
either gene targeting or knockout mouse studies. TrkA
mainly binds NGF, TrkB interacts with BDNF, while
TrkC is the putative high-affinity receptor for NT-3
(Chao, 1992; Chao and Bothwell, 2002; Fig. 3).
Developmental changes in NT dependence parallel the
increase in p75NTR production coincident with the pro-
gression of melanocytes to malignant melanoma. There are
a number of reasons why NTRs are upregulated in mela-
noma. Melanoma cells frequently exhibit genetic insta-
bility (Nicolson, 1987). Second, because melanoma has
the same developmental origin as neuroectodermal cells
(Yaar and Gilchrest, 1991), a predisposition to switching
expression of NTR genes is not unlikely. Those that
upregulate NTRs are more apt to survive in the brain.
Finally, 12-O-tetradecanoylphorbol-13-acetate has also
been shown to induce p75NTR and other TRK receptors
in melanocytes (Peacocke et al., 1988; Yaar and Gilchrest,
1991; Yaar et al., 1994). Interestingly, primary melanocyte
cultures express low levels of TrkC that are enhanced by
12-O-tetradecanoylphorbol-13-acetate stimulation (Pea-
cocke et al., 1988; Yaar and Gilchrest, 1991; Yaar et al.,
1994). Our laboratory has observed high levels of both
p75NTR and TrkC expression in melanoma cells (Her-
rmann et al., 1993; Marchetti et al., 2003a). Importantly,
the presence of these NTRs (p75NTR, TrkC) in brain-
metastatic melanoma resulted in enhancement of mela-
noma cell invasion (Marchetti and Nicolson, 1997a, b;
Marchetti et al., 1996; Nicolson et al., 1994). Furthermore,
we have recently reported that TrkC receptor functionality
in these cells occurs via the association of TrkC with a
purine-analog sensitive kinase (Marchetti et al., 2003a).
Based upon the observed NTR overexpression in brain-
metastatic melanoma cells and NT regulation of their in-
vasive properties (see below), we have formulated the
hypothesis that brain metastases essentially represent a
traumatic event related to brain-injury processes. Follow-
ing mechanical or chemical brain insults, NT synthesis is
increased and NT/NTR presence is imperative in neuronal
regeneration (Chao and Bothwell, 2002). These changes
are paralleled by brain-invasive melanoma cells whose
invasion and colonization within the brain microenviron-
ment triggers NT production and secretion by surround-
Fig. 2. Schematic representation of the 2 different classes of neu-
rotrophin receptors (p75NTR, TRK: TrkA, TrkB, TrkC). The p75NTR is a
glycoprotein containing 4 cysteine-rich domains in its extracellular
portion but no intracytoplasmic tyrosine kinase (TK) domain. How-
ever, p75NTR is capable of signaling independent of TRK presence,
amplifying the TRK signal when TRK is present (Chao and Bothwell,
2002). TRK receptors contain a signal peptide sequence, cystein
clusters, and leucine-rich and Ig-like regions in their extracellular
domains and possess an intracytoplasmic TK domain. Percentages
of similarity between the 3 main TRK receptors (TrkA, TrkB, TrkC)
for their extracellular region/TK domain are respectively indicated.
Fig. 3. Functional cross-reactivities among neurotrophins and neu-
rotrophin receptors (p75NTR and TRK). P75NTR binds all NT members
equally well. The primary ligand for each TRK receptor is indicated
by heavy arrows. Black heavy arrows denote interactions between
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ing brain cells. Similarly, melanoma cells overexpressing
NTRs (p75NTR, TrkC) can benefit from such a synergistic
microenvironment in terms of survival, growth, and fur-
ther invasion into the brain parenchyma (Nicolson et al.,
1996). We suggest that NTRs may play important roles
in melanoma progression to the brain while NT-regulated
heparanase can be critical to this process. Although we
have validated this hypothesis with in vitro models of
brain-metastatic melanoma, further supporting evidence
must be obtained by in vivo experiments. 
Neurotrophin Receptor Signaling Mechanisms
The complexity of functional interactions between p75NTR
and TRK receptors rivals that of other complex receptor
systems (Chao and Bothwell, 2002; Hempstead et al.,
1991; Lee et al., 1992, 1994; Verdi et al., 1994). It is gen-
erally agreed that TK receptors are involved in sequences
of events that include ligand binding, leading to receptor
dimer formation and transactivation, resulting in tyrosine
phosphorylation, with the eventual activation of serine/
threonine (ser/thr) phosphorylation cascades (Barbacid,
1993; Chao, 1992; Meakin and Shooter, 1992; Ohmichi et
al., 1991, 1992b; Saltiel and Decker, 1994). Active signal-
ing complexes are frequently formed by interactions
between receptor phosphotyrosines and proteins contain-
ing SH2, or Src homology-2, tyrosine-binding domains
(Avruch et al., 1994; Batistatou et al., 1992; Borrello et al.,
1994; Lange-Carter and Johnson, 1994; Obermeier et al.,
1993a, b, 1994; Ohmichi et al., 1994; Rozakis-Adcock et
al., 1992; Satoh et al., 1992; Stephens et al., 1994; Taylor
et al., 1994). Formation of this complex leads to tyrosine
phosphorylation on Shc and the association of Shc with
Grb2, another SH2-containing protein (Borrello et al.,
1994; Obermeier et al., 1993a, b, 1994; Ohmichi et al.,
1994; Stephens et al., 1994). The association of Shc with
Grb2 can lead to further complex formation with the
p21ras nucleotide exchange factor Son of sevenless-1 
(Sos-1). This may result in increased GTP binding and acti-
vation of p21ras, a GTP-binding oncoprotein originally
identified in a rat sarcoma virus (Satoh et al., 1992).
The downstream effectors of p21ras include proteins
involved in ser/thr phosphorylation cascades (Avruch et
al., 1994). Studies have demonstrated that p21ras can
coordinate the NGF-mediated, phosphorylation-dependent
activation of several key growth and differentiation mol-
ecules (Kaplan and Miller, 2000), including (1) c-Raf-1,
a cytoplasmic ser/thr kinase discovered as the oncopro-
tein v-raf in a mouse sarcoma virus, (2) the mitogen-acti-
vated protein kinase/extracellular-signal-regulated kinase
(MAPK/ERK [MEK]), and (3) MAPK. The activation of
MAPK can transiently induce the expression of a num-
ber of primary response genes that encode transcription
factors, such as c-fos, c-jun, NGFI-B, and kirx24 (Batis-
tatou et al., 1992). The MAPK activity can also affect
other ser/thr kinases and cytoskeletal elements (Kaplan
and Miller, 2000; Taylor et al., 1994). MEKK, a ser/thr
kinase that can activate MEKs independently of c-Raf-1,
has been observed to phosphorylate MEK in PC12 cells
as they respond to NGF (Kaplan and Miller, 2000;
Lange-Carter and Johnson, 1994).
Coexpression of p75NTR and TrkA resulted in increases
in downstream signaling and NT responses, including
mitotic arrest following neurite extension and neuronal
maturation, relative to cells expressing only TrkA (Bar-
bacid, 1993; Berg et al., 1991; Chao, 1992; Hempstead et
al., 1989). According to another model, p75NTR procures
and presents bound NT molecules to members of the
TRK receptor tyrosine kinase family to initiate signal
transduction (Chao, 1992; Chao and Bothwell, 2002).
Table 1. Receptors and ligands  
Receptor Ligand* Characteristics**  
p75NTR NGF, BDNF, NT-3, NT-4/5 Lacks tyrosine kinase domain   
Binds all TRK receptors  
Possesses a signaling function independent of TRK receptors  
Provides differentiation and survival cues to neuronal tissues  
Triggers apoptosis in certain virally transformed neuronal cells  
Triggers survival when expressed in neutrophils    
TrkA NGF Tyrosine kinase intracytoplasmic domain  
NT-3 Omission produces defects in the cervical ganglia of mice    
TrkB BDNF Tyrosine kinase intracytoplasmic domain  
NT-3, NT-4/5 Influences vestibular ganglia    
TrkC NT-3 Tyrosine kinase intracytoplasmic domain  
Regulates proliferation and survival of neuronal precursors   
Regulates the collateral branching of axons into target fields  
Abbreviation: TRK, tropomyosin receptor kinase.
*The primary ligands are indicated in plain text. Secondary neurotrophin cross-reactivities are listed in italics.
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Little is known about p75NTR cooperative interactions
with other NTRs, but recent evidence based on anti-
p75NTR antibody injections into chick embryos suggests
that BDNF and NT-3 may cooperate with p75NTR to
form functional signaling pathways (von Bartheld et al.,
1994). Collectively, these data emphasize the importance
of cooperativity between the TRK family of receptors
and p75NTR for enhancing NT capabilities of cells. Bio-
chemical and functional interactions between TrkA and
p75NTR have also been detected after co-immunoprecip-
itation and Western blotting (Bibel et al., 1999). 
Dependent upon the cellular context in which it is
expressed, p75NTR shows alternative functions independ-
ent of TRK presence. In addition to receiving differentia-
tion or survival signals in neuronal cells, p75NTR provides
retrograde transport in certain neuronal cell types (Verdi
et al., 1994), triggering apoptosis in certain virally trans-
formed neuronal cells (Rabizadeh et al., 1993) or survival
when expressed in neutrophils (Kannan et al., 1992). 
The p75NTR cytoplasmic tail contains a 14-amino acid
mastoparan-like domain (Feinstein and Larhammar,
1990; Johnson et al., 1986). Activation of a G-stimulatory
protein complex in the presence (or absence) of NGF may
lead to the production of cyclic AMP (cAMP) by adeny-
late cyclase and activation of protein kinase A, followed
by transcription factor activation (Knipper et al., 1993).
Transfection studies involving sequence deletions in
p75NTR of small segments in the cytoplasmic tail proved
that these deletions are essential for high-affinity NGF
binding involving TrkA in PC12 and NIH3T3 cells (Hant-
zopoulos et al., 1994; Hempstead et al., 1990). Certain
properties of p75NTR also allow it to function in regulat-
ing survival and death of melanoma cells. In this regard,
p75NTR is analogous to members of the tumor necrosis
factor (TNF) receptor superfamily, such as Fas (Apo I),
TNFRI, and TNFRII, and the B cell antigen CD40, all of
which regulate programmed cell death (Beutler and van
Huffel, 1994; Smith et al., 1994). Therefore, it is apparent
that p75NTR plays a bifunctional role as a molecular
switch that signals either cell survival or cell death (Bar-
rett and Bartlett, 1994). 
Of relevance, a ser/thr protein kinase that is sensitive
to purine analogs and known as protein kinase N (PKN)
has been isolated with p75NTR following NGF stimulation
of PC12 cells (Volonté et al., 1993; Volonté and Greene,
1992). The activation of this PKN in association with
stimulation of ornithine decarboxylase activity plays a
potentially important role in the signaling pathways asso-
ciated with p75NTR (Ohmichi et al., 1991). We have re-
cently demonstrated that there is an association between
TrkC receptors and a purine-analog-sensitive kinase in
human brain-metastatic melanoma cells (Marchetti et al.,
2003a). We have also determined that this kinase is sim-
ilar to the one known to associate with p75NTR and pos-
sesses an activity under the specific regulation by TrkC
putative ligand, NT-3 (Marchetti et al., 2003a). There-
fore, purine-analog-sensitive kinases like PKN can repre-
sent a signaling component(s) common to NTR, playing
roles in melanoma cell pathogenesis by generating con-
stitutive downstream signaling. In relation to p75NTR, the
cooperative interaction of downstream signals from
p75NTR/PKN in amplifying signals pre-established by
TRK may be important in brain-metastatic melanoma. 
In this case, when NT concentrations are high, the low-
affinity activation of p75NTR/PKN signals amplify the
TRK response pathway. In contrast, when NT levels are
low, p75NTR signals are driven along an alternate path-
way, allowing p75NTR to act as a sensitive molecular
switch because of its low affinity for NTs. 
Activation of the sphyngomyelin cycle serves as an
alternate signaling pathway for p75NTR (Dobrowsky et
al., 1994). The sphyngomyelin pathway also seems to be
important during signaling by TNF receptors (p75NTR
is a member of the TNF receptor superfamily), and this
pathway appears to involve a ceramide-activated protein
phosphatase (Wolff et al., 1994). This alternate form of
signal transduction by p75NTR may be important to cells
invading the brain. Brain tissue injured by tumor cell
invasion can provide a ready source of ceramide that
might also influence invading cells.
Neurotrophin Receptors and Progression 
of Malignant Melanoma Cells
During malignant progression, melanoma cells show
progression-associated increases in the expression of
p75NTR (Herlyn et al., 1985; Nicolson et al., 1996), as
witnessed by in situ examination of p75NTR levels in
advanced stages of malignant melanoma (Ross et al.,
1984; Marchetti et al., 1995). Human melanoma cells
established in short-term tissue culture from brain metas-
tases exhibit characteristic chromosomal alterations
(Morse et al., 1992). Importantly, although p75NTR
expression was not examined in these cells (Morse et al.,
1992), the gene is located at 17q21-22 and may be ampli-
fied in tumor cells containing the isochromosome. 
We have examined the role of NTs and NTRs in brain
invasion and colonization of malignant melanomas. Using
the human melanoma variant cell subline 70W, which
has the capacity to form brain colonies in nude mice, we
have studied the effects of NTs and growth factors on
their malignant properties. The 70W subline was derived
as one of the series of human MeWo melanoma cell vari-
ants selected by treatment with wheat germ agglutinin
(Ishikawa et al., 1988). Parental MeWo cells exhibit in-
termediate metastatic potential as compared with other
cell lines such as the nonmetastatic 3S5 and the brain-
metastatic 70W cell variants. Of note, 3S5 and 70W cells
possess opposite metastatic capabilities when injected in
vivo in nude mice: While 3S5 cells are nonmetastatic, 70W
cells are highly aggressive and brain-metastatic (Mar-
chetti et al., 1993), being the first reported example of
human melanoma cells capable of metastasizing to the brain
when injected intravenously in nude mice (Ishikawa et
al., 1988). Furthermore, target organ site colonization by
the 70W line is similar to the clinical presentation of mela-
noma metastasis. Using the MeWo melanoma cellular
system (MeWo parental, 3S5, and 70W variants), we have
shown that overexpression of p75NTR is associated with
brain colonization, enhancement of extracellular matrix
(ECM) invasion (Herrmann et al., 1993; Marchetti et al.,
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Neurotrophins Enhance Invasion and Heparanase
Production in Brain-Metastatic Melanoma Cells
During metastasis formation, migrating tumor cells are
confronted by natural tissue barriers that surround the
blood vessels, such as BM (Gladson et al., 1995; Liotta
et al., 1991), or ECM, which is an integral part of the
BBB. The ability of malignant cells to penetrate these bar-
riers depends upon the production and activation of
enzymes capable of ECM degradation (Liotta et al.,
1982; Powell and Matrisian, 1996; Sloane and Honn,
1984). ECM and BM are rigid structures formed from
macromolecules such as type IV collagen, laminin, entactin,
nidogen, fibronectin, and proteoglycans (Iozzo and Mur-
doch, 1996), one type being heparan sulfate (HS) pro-
teoglycans, or HSPGs. It is known that HSPGs play a
central role in embryonic morphogenesis, angiogenesis,
neurite outgrowth, and tissue repair (Bernfield et al.,
1999; Iozzo, 1988; McKeehan and Kan, 1994; Yanag-
ishita and Hascall, 1992). ECM and BM HSPGs also
provide a readily available storage depot for growth fac-
tors and cytokines (Vlodavsky and Friedmann, 2001).
Since HSPGs are now recognized as active biological
modulators, their degradation at the level of HS chains is
expected to have significant regulatory consequences in
cancer metastasis (Bernfield et al., 1999). Indeed, HSPG
catabolism is observed in inflammation, wound repair,
diabetes, and neoplasia, including melanoma (Marchetti,
1997; Nakajima et al., 1988). Melanoma heparanase
responsible for HS degradation cleaves HS at specific
intrachain sites, which results in the formation of frag-
ments of discrete molecular weight size (Marchetti, 1997;
Nakajima et al., 1986a). Therefore, heparanase was iden-
tified as an endo--D-glucuronidase (Nakajima et al.,
1986b, 1988). Importantly, heparanase differs from
heparinases or other HS-specific elimination enzymes
(bacterial heparitinases), which are eliminases indiscrim-
inately cleaving HS to disaccharide and/or tetrasaccha-
ride units. Heparanase activities have also been described
in the immune system and in cancer cells other than
melanoma (Nakajima et al., 1988; Vlodavsky and Fried-
mann, 2001; Vlodavsky et al., 1999). Increased levels of
heparanase activity are associated with metastatic
melanoma and other invasive tumors types, and copi-
ous evidence has demonstrated its role in tumor cell inva-
sion into distant organs (Nakajima et al., 1988; Vlo-
davsky and Friedmann, 2001). 
By examining the heparanase/HSPG axis in brain-
metastatic melanoma, we have demonstrated the fol-
lowing: (1) highly brain-invasive human melanoma cells
degrade purified ECM HS and HS cell-surface subpop-
ulations faster than sublines of lower metastatic poten-
tial (Marchetti et al., 1993, 1996; Walch et al., 1999); 
(2) heparanase is responsible for this HS degradation
(Marchetti, 1997; Marchetti et al., 1996); (3) in direct
correlation with both increased invasiveness and pres-
ence of their specific NTR, select NT members augment
heparanase production in brain-metastatic melanoma,
which makes it a major candidate enzyme responsible for
ECM degradation (Marchetti and Nicolson, 1997b; 
Marchetti et al., 1993, 1995, 1996); and (4) heparanase
recognizes specific motifs within HS chains associated
with both the binding domains to angiogenic factors and
to an HS-interacting protein, HIP, which was recently
cloned and characterized (Marchetti et al., 1997b). 
Of note, human heparanase had not been purified nor
well characterized or cloned until 1999 (Hulett et al.,
1999; Kussie et al., 1999; Toyoshima and Nakajima,
1999; Vlodavsky et al., 1999). Therefore, molecular tools
to explore the potentially important roles of heparanase
in disease have been lacking for almost 25 years follow-
ing the first reports describing its enzymatic activity.
Interestingly, the newly discovered cDNA sequences of
human heparanase that is derived from normal and
tumor cells represent the same gene (Hulett et al., 1999;
Kussie et al., 1999; Toyoshima and Nakajima, 1999; Vlo-
davsky et al., 1999). 
We have postulated that heparanase plays 2 critical
roles in the biology of brain metastasis, which are (1) in
local invasive processes by degrading the HS chains of
HSPGs and (2) in the release of HS-bound angiogenic
factors at the metastatic site, with the brain considered
the ideal environment because of its high levels of NT
production. Heparanase can therefore be dually relevant
in brain-metastatic melanoma in consideration of the
strong angiogenic properties exhibited by melanoma cells
in the brain. In fact, although metastasizing cancer cells
may produce as many as 28 different matrix-digesting
proteases, the new findings show that there is only 1 hep-
aranase. Heparanase inhibition not only inhibits the 
ability of cancer cells to invade but also hinders the for-
mation of new blood vessels that feed tumors, or angio-
genesis (Folkman, 2001).
To determine if poorly metastatic melanoma cells
acquire an increased metastatic potential following
heparanase gene upregulation, we constructed eukary-
otic expression vectors that contained the full-length
human heparanase cDNA and used them to transfect
melanoma cells. Transfection of the human heparanase
gene into cells of low invasive potential and heparanase
content resulted in functional enzymatic activity and in
significantly increased (7- to 14-fold) invasion of trans-
fected cells, as demonstrated by using in vitro chemo-
invasion assays with purified HSPG as an invasive bar-
rier (Marchetti and Nicolson, 2001).
Equally relevant to the area of brain invasion and
metastasis is assessing heparanase contributions to angio-
genic events. Extracellular matrix HSPGs serve as a reser-
voir for angiogenic factors, such as basic fibroblast growth
factor (bFGF), that can be extracted from subendothelial
ECM produced in vitro (Aviezer et al., 1997; McKeehan
and Kan, 1994). Displacement of bFGF from the ECM
by heparanase can provide a novel mechanism for induc-
tion of neovascularization in normal and pathological
conditions (Rodeck et al., 1991). Several studies have
indicated that heparin and HS inhibit the mitogenic
activity of angiogenic bFGF and at the same time stabi-
lize and protect the molecule from inactivation (Gospo-
darowicz and Cheng, 1986). Basic fibroblast growth fac-
tor is stored in the ECM in a highly stable, inactive form.
Its release from ECM as a complex with HS fragments
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bFGF and capable of binding the high-affinity plasma-
membrane receptors. 
Since the abilities of bFGF to bind ECM HSPG and to
act as a potent angiogenic factor have long been recog-
nized (Folkman, 2001), we have evaluated the ability of
purified human heparanase to modulate bFGF activity
and its release from ECM HSPG by using the rabbit ear
chamber method. This in vivo angiogenic assay has been
used for the past 50 years as a well-controlled in vivo
model to study angiogenesis, wound healing, and tissue
responses. Implantation of HSPG-bFGF beads previously
incubated with purified heparanase into rabbit ear cham-
bers produced a significantly increased vascularization
(Marchetti et al., 2003b). Furthermore, inhibition of
heparanase-induced angiogenesis was achieved in the
presence of a selected group of suramin analogues as
newly developed potent angiogenic inhibitors, which
demonstrates that these reagents inhibited heparanase-
mediated degradation of subendothelial ECM (Marchetti
et al., 2003b). These results further emphasize the impor-
tance of heparanase in brain invasive and angiogenic
mechanisms (Vlodavsky and Friedmann, 2001) and the
potential clinical application of heparanase inhibitors,
such as suramin analogs or others, in angiogenic-dependent
cancers like brain-metastatic melanoma.
Brain Tissue Neurotrophin Production at the
Melanoma Tumor Invasion Front
Since growth factor production could influence the inva-
sion and growth of melanoma cells in the brain, we have
examined human brain-metastatic melanoma (70W) cells
for synthesis of NT-regulating factors and for the pres-
ence of growth factor transcripts. Reverse transcriptase-
polymerase chain reaction analysis revealed the produc-
tion of NT-regulating transforming growth factor
(TGF)-1 and bFGF, as well as other factors such as
TGF- and interleukin-1 (Menter et al., 1994). Some of
these factors can stimulate brain astrocytes or oligoden-
drocytes to produce NT. We reasoned that, because mela-
noma cells could produce NT-regulating factors, these
factors might influence NT production in the brain.
Therefore, we have investigated whether brain-invading
melanoma cells induced changes in NT concentration or
NT distribution at the brain invasion front of melanoma
tumors in vivo. Brain-tissue samples from human mela-
noma metastases and uninvolved brain tissues in adja-
cent sections were examined immunohistochemically for
NT presence. Staining of serial sections with anti-NT
monoclonal antibodies revealed increased concentrations
of NT (in particular, NGF and NT3) in tumor-adjacent
tissues. Staining was highest at the interface between the
melanoma tumor and adjacent normal brain tissue and
gradually decreased in concentration until NTs were
undetectable at more distant sites (Marchetti et al.,
1995). Using these methodologies, we observed that con-
trols without primary antibody or uninvolved brain tis-
sue progressively distant from the melanoma lesion pos-
sessed very low or undetectable levels of NT (Marchetti
et al., 1995).
Enhancement by Astrocytes, 
Brain Environment, and Cellular Responses
Astrocytes Contribute to the Brain-Metastatic
Specificity of Melanoma Cells by Producing
Heparanase
Astrocytes, which are among the first brain cells encoun-
tered by extravasating melanoma cells, produce NT
(Yoshida and Gage, 1992). In addition, they are capable
of binding NT because they express members of the
TRK receptor family and p75NTR (Yoshida and Gage,
1992). Futhermore, they are relevant because astroglio-
sis can be at times a pathologic trauma in response to
brain-invasive events: Injury-reacting astrocytes are fre-
quently found in areas surrounding melanotic lesions.
Astrocytes can therefore play important roles in the
development of brain metastases. To test this hypothesis,
we have employed purified in vitro astrocytic cultures
and investigated the presence of heparanase. Primary
glial cells were obtained from newborn rat and mouse
cerebra by established purification methods (McCarthy
and de Vellis, 1980). Their identification as astrocytes
was confirmed by positive immunoreactivity with an
antibody against the astrocyte-specific, intermediate-
filament glial fibrillary acidic protein GFAP (McCarthy
and de Vellis, 1980). We next examined the astrocyte cul-
tures for expression of heparanase. A specific hepara-
nase transcript was detected by semiquantitative reverse
transcriptase-polymerase chain reaction. This transcript
was upregulated 3-fold in astrocytes previously incubat-
ed with purified and biologically active NGF (Marchetti
et al., 2000). Similar results were obtained with human
brain-metastatic 70W cells. Heparanase activity was
also detectable and NGF regulated in cellular extracts
from both purified astrocytes and brain-metastatic cells.
This was shown by the appearance of distinct HS degra-
dation products detected in agarose gel shift assays or
by high-speed gel permeation column chromatography
(high-performance liquid chromatography analysis;
Marchetti et al., 2000). 
Second, we analyzed heparanase activity in brain-
metastatic melanoma cells and astrocytic cell populations
in logarithmic growth by obtaining high-performance
liquid chromatography–derived elution profiles of HS-
digested products at various incubation times (Marchet-
ti et al., 1993). Cultures of highly brain-metastatic 70W
cells showed a gradual and time-dependent increase in
heparanase activity for up to 72 h. After this time inter-
val, the heparanase levels in cultures plateaued. Interest-
ingly, cultures of astrocytes also produced heparanase
in a time-dependent manner. Moreover, coincubation of
brain-metastatic melanoma cells and astrocytes in equi-
cellular numbers resulted in a superadditive increase of
enzymatic activity, greater than that expected for both
cell types. 
Finally, we incubated brain-metastatic melanoma cells
with astrocyte-conditioned medium (ACM) and exam-
ined its effects on their invasive characteristics. We found
consistent increases in in vitro invasion following expo-
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nounced when ACM from NGF-treated astrocytes was
used, and the invasion effects of ACM were completely
abrogated in the presence of heparanase antibodies
(Marchetti and Nicolson, 2001). The invasion enhance-
ment caused by this NGF treatment was also abolished
in the presence of a neutralizing NGF monoclonal 
antibody, which confirms the relevance of melanoma/
astrocyte heparanase and its NT-regulation to brain inva-
sion events.
The Brain as a Unique Compartment for the Invasion
and Growth of Malignant Melanoma Cells
Homeostasis and the control of material flow into the
brain is strictly regulated by the BBB. Brain-metastatic
cells must breach this formidable barrier to invade and
colonize the brain parenchyma. As discussed above, inva-
sion of the brain requires that metastatic cells increase
their expression of certain cell surface receptors (NTRs),
degradative enzymes (heparanase), and growth factors
and cytokines (TGF/, bFGF, interleukin-1, and oth-
ers). They must also respond to invasion-stimulating
cytokines such as NTs and paracrine growth factors.
Brain-metastasizing melanoma cells express relatively
high levels of BM hydrolytic enzymes such as type IV col-
lagenases, cathepsins, plasminogen activators, and of rel-
evance, heparanase. Although highly metastatic cells gen-
erally express higher amounts of degradative enzymes
than nonmetastatic cells, some of these enzymes are in-
duced to even higher levels by the microenvironment
(paracrine invasion factors) or are provided by certain
normal cells (microvessel endothelial cells and astrocytes,
among others; Nicolson et al., 1994, 1996). If the appro-
priate paracrine signals are received by malignant cells,
they can be stimulated to increase the synthesis and
release of BBB-degrading enzymes. 
Cellular Responses to Brain Tissue Injury as a
Paradigm for Brain Metastasis
Astroglial cells constitute the primary cellular response
following brain injury (Norenberg, 1994). Astrocytes are
the predominant cell type in the brain, outnumbering
neurons by a factor of 10 to 1. By numbers, astrocytes
make up one third of the cerebral cortex; however, as a
population of cells they are widely heterogenous (Ket-
tenmann et al., 1983; Wilkin et al., 1990). One of the ear-
liest pathological responses to brain trauma involves
astrocyte swelling occurring predominantly in the perivas-
cular astrocytic endings (Hirano et al., 1994; Kimelberg
and Ransom, 1986). In experimental brain tumors, cere-
bral edema has been associated with significant alter-
ations in vascular permeability (Lantos et al., 1984). If
the BBB is compromised, astrocyte swelling may involve
vasogenic edema. In this case, the astrocytes swell as they
take up proteins and water that may become cytotoxic
because of increased potassium and glutamate (Hirano
et al., 1994; Klatzo et al., 1980; Norenberg, 1994). It is
generally believed that astrocyte swelling is caused by
increases in intracellular osmolarity followed by water
influx. This can occur without loss of BBB integrity and
perhaps simply represents a redistribution of water from
the neuronal to the astrocytic cell compartment. This
form of astrocyte swelling is generally not as severe as the
astrocyte swelling that can result from vasogenic edema
associated with the trauma caused by tumor cell inva-
sion. If astrocyte swelling becomes too severe, it can
cause depolarization of astroglial cells, leading to the loss
of homeostatic ion gradients and membrane rupture,
resulting in cell death. These dynamic astrocyte changes
in response to tumor cell invasion can lead to increased
intracranial pressure and further complications. The
tumor-induced response by astrocytes is being investi-
gated as a cause, or one of the causes, of brain metastases
causing severe symptoms such as paralysis, headache,
seizures, and impaired cognition.
Vasogenic edema leads to the influx of thrombin,
platelet-derived growth factor, steroids, insulin, and var-
ious cytokines from the blood and lymphocytes, as well
as endothelin, ATP, and bFGF from endothelial cells 
(Fig. 4). The induction of reactive astrocytes, when asso-
ciated with tumor cell invasion, is likely triggered by
endogenous factors in the brain in addition to those pro-
vided by the invading tumor cells (Fig. 4). We have
observed reactive gliosis in brain tissue associated with
the melanoma invasion front, illustrating the cellular
response of the adjacent brain tissue (Nicolson et al.,
1996). In addition to morphological changes, the adjoin-
ing brain cells produce high levels of NTs in comparison
with uninvolved brain tissue (Marchetti et al., 1995).
Thus, brain-metastatic melanoma cells may induce the
production of brain cytokines such as NTs that aid in the
invasion and survival of melanoma cells in the CNS.
Concluding Remarks and 
Scientific Challenges
The points raised in this review raise questions more than
provide answers in dealing with brain-metastatic mela-
noma. Clearly, we have much more to learn about the
mechanisms used by melanoma cells in colonizing the
brain. Some of the scientific challenges are the following.
1. There is no simple mechanism that can explain the
organ preference of brain metastasis. Although we
know much more about the growth and invasive
properties of brain-metastatic melanoma cells, we
are now beginning to identify melanoma and brain
properties involved in brain metastasis. Nonethe-
less, some of these properties, such as the expres-
sion of cell-surface NTRs, response to NTs, and
production/secretion of NT-regulated heparinase,
may be general properties of tumor cells that
metastasize to the brain.
2. Various brain cells other than astrocytes may con-
tribute enzymes, motility factors, growth factors,
growth inhibitors, and many other cytokines that
have not yet been fully characterized. These may
provide an appropriate microenvironment for in-
vasion and brain colonization by brain-metastatic
melanoma cells. This needs further research em-
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we must obtain a greater understanding of the
brain microenvironment and the reciprocal cyto-
kine regulation of growth. Because many of the
cytokines involved in brain metastasis are effective
at stimulating both the brain tissue and invading
melanoma cells, this will be one of the most diffi-
cult problems to decipher.
3. The frequency of distribution of certain cancers to
sites that follow their developmental potentials
suggests that inappropriately expressed develop-
mental genes could contribute to the organ prefer-
ence of metastasis. Unfortunately, we know little
about the developmental processes that control
embryonic cell motility and organ colonization by
normal cells during development. It is interesting,
however, to note that NTs are important mole-
cules, signaling growth and differentiation of spe-
cific neuronal cell subpopulations at specific times
during development. It may not be a coincidence
that brain-metastatic melanoma cells may use
paracrine NTs as source of growth in the brain.
This will require further research efforts by per-
forming in vivo experiments to validate causative
roles of the NT/NTR axis and heparanase in
melanoma brain invasion in vivo. 
4. Challenges in growth factor and growth inhibitor
responses during melanoma progression may be
important to the continued survival and growth of
malignant cells in secondary compartments, and
these challenges are probably driven by the selec-
tive pressures of the host. The inherent instability
of malignant cells presents a daunting problem
because it is likely that the most unstable, rapidly
progressing melanoma cells will be the ones that
metastasize to critical sites like the brain and resist
therapy.
The implications of these unsolved phenomena in brain
metastasis may be particularly profound for the brain
tumor biologist, the neuro-oncologist, and, most impor-
tantly, the brain cancer patient affected with such dev-
astating disease.
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Fig. 4. Reciprocal interactions between brain-invading melanoma cells and normal cells in the brain microenvironment. Tumor cells release
cytokines that can affect host cells such as parenchymal cells, endothelial and glial cells, astrocytes, and brain tissue extracellular matrix (ECM).
Reactive astrocytes can arise from stimulation by factors released by invading melanoma cells. In turn, brain cells can release factors that stim-
ulate tumor cell motility and invasion. Astrocytes, oligodendrocytes, and neurons can release NT and ECM degradative enzymes, for exam-
ple, heparanase produced by astrocytes (Marchetti et al., 2000) in response to brain-invading melanoma. Conversely, these cells secrete
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